Combretastatin A-4 inhibits cell growth and metastasis in bladder cancer cells and retards tumour growth in a murine orthotopic bladder tumour model

British Journal of Pharmacology

Volumn 160, Issue 8, 2010, Pages 2008-2027

  Shen, Cheng Huang ^a   Shee, Jia Jen ^b   Wu, Jin Yi ^c   Lin, Yi Wen ^c   Wu, Jiann Der ^a   Liu, Yi Wen ^c  

^a CHIA YI CHRISTIAN HOSPITAL   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c NATIONAL CHIAYI UNIVERSITY   (Taiwan)

Author keywords

apoptosis; bladder cancer; combretastatin A 4; intravesical chemotherapy; mitotic catastrophe; murine orthotopic bladder tumour model

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ALPHA TUBULIN; BETA ACTIN; CASPASE 3; COMBRETASTATIN A4; PROPIDIUM IODIDE; ANTINEOPLASTIC AGENT; COMBRETASTATIN A4 PHOSPHATE; PROTEIN KINASE B; STILBENE DERIVATIVE; TUBULIN MODULATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER INHIBITION; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL MIGRATION; CELL SURVIVAL; CLONOGENESIS; DRUG CYTOTOXICITY; DRUG MECHANISM; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; METASTASIS INHIBITION; MICROTUBULE ASSEMBLY; MITOSIS; MOUSE; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; TUMOR MODEL; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CELL MOTION; CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFECTS; IC50; METABOLISM; MICROTUBULE; PATHOLOGY; PHOSPHORYLATION; TIME; TUMOR CELL LINE; TUMOR INVASION; TUMOR VOLUME; URINARY BLADDER NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; MICE; MICE, INBRED C57BL; MICROTUBULES; NEOPLASM INVASIVENESS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; STILBENES; TIME FACTORS; TUBULIN MODULATORS; TUMOR BURDEN; URINARY BLADDER NEOPLASMS;

EID: 77954882234     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.00861.x     Document Type: Article

References (47)

1. Amling CL (2001). Diagnosis and management of superficial bladder cancer. Curr Probl Cancer 25 : 219 278.
2. Barocas DA, Clark PE (2008). Bladder cancer. Curr Opin Oncol 20 : 307 314.
3. Bilenker JH, Flaherty KT, Rosen M, Davis L, Gallagher M, Stevenson JP et al. (2005). Phase I trial of combretastatin a-4 phosphate with carboplatin. Clin Cancer Res 11 : 1527 1533.
4. Black PC, Dinney CP (2007). Bladder cancer angiogenesis and metastasis - translation from murine model to clinical trial. Cancer Metastasis Rev 26 : 623 634.
5. de Bruin EC, Medema JP (2008). Apoptosis and non-apoptotic deaths in cancer development and treatment response. Cancer Treat Rev 34 : 737 749.
6. Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R, Kroemer G (2004). Cell death by mitotic catastrophe: a molecular definition. Oncogene 23 : 2825 2837.
7. Chade DC, Andrade PM, Borra RC, Leite KR, Andrade E, Villanova FE et al. (2008). Histopathological characterization of a syngeneic orthotopic murine bladder cancer model. Int Braz J Urol 34 : 220 226. discussion 226-229.
8. Cheng YT, Li YL, Wu JD, Long SB, Tzai TS, Tzeng CC et al. (1995). Overexpression of MDM-2 mRNA and mutation of the p53 tumor suppressor gene in bladder carcinoma cell lines. Mol Carcinog 13 : 173 181.
9. Cooney MM, Radivoyevitch T, Dowlati A, Overmoyer B, Levitan N, Robertson K et al. (2004). Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer. Clin Cancer Res 10 : 96 100.
10. Dachs GU, Steele AJ, Coralli C, Kanthou C, Brooks AC, Gunningham SP et al. (2006). Anti-vascular agent Combretastatin A-4-P modulates hypoxia inducible factor-1 and gene expression. BMC Cancer 6 : 280.
11. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ (1997). Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 57 : 1829 1834.
12. Davis FM, Tsao TY, Fowler SK, Rao PN (1983). Monoclonal antibodies to mitotic cells. Proc Natl Acad Sci USA 80 : 2926 2930.
13. Escargueil AE, Plisov SY, Filhol O, Cochet C, Larsen AK (2000). Mitotic phosphorylation of DNA topoisomerase II alpha by protein kinase CK2 creates the MPM-2 phosphoepitope on Ser-1469. J Biol Chem 275 : 34710 34718.
14. Folkman J (2002). Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29 : 15 18.
15. Fuchs E, Karakesisoglou I (2001). Bridging cytoskeletal intersections. Genes Dev 15 : 1 14.
16. Gee J, Sabichi AL, Grossman HB (2002). Chemoprevention of superficial bladder cancer. Crit Rev Oncol Hematol 43 : 277 286.
17. Greene LM, Campiani G, Lawler M, Williams DC, Zisterer DM (2008). BubR1 is required for a sustained mitotic spindle checkpoint arrest in human cancer cells treated with tubulin-targeting pyrrolo-1,5-benzoxazepines. Mol Pharmacol 73 : 419 430.
18. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009). Cancer statistics, 2009. CA Cancer J Clin 59 : 225 249.
19. Kanthou C, Greco O, Stratford A, Cook I, Knight R, Benzakour O et al. (2004). The tubulin-binding agent combretastatin A-4-phosphate arrests endothelial cells in mitosis and induces mitotic cell death. Am J Pathol 165 : 1401 1411.
20. Kim I, Xu W, Reed JC (2008). Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities. Nat Rev Drug Discov 7 : 1013 1030.
21. Kuo CC, Hsieh HP, Pan WY, Chen CP, Liou JP, Lee SJ et al. (2004). BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo. Cancer Res 64 : 4621 4628.
22. Kuo PL, Hsu YL, Cho CY (2006). Plumbagin induces G2-M arrest and autophagy by inhibiting the AKT/mammalian target of rapamycin pathway in breast cancer cells. Mol Cancer Ther 5 : 3209 3221.
23. Lin HL, Chiou SH, Wu CW, Lin WB, Chen LH, Yang YP et al. (2007). Combretastatin A4-induced differential cytotoxicity and reduced metastatic ability by inhibition of AKT function in human gastric cancer cells. J Pharmacol Exp Ther 323 : 365 373.
24. Lower GM, Jr. (1982). Concepts in causality: chemically induced human urinary bladder cancer. Cancer 49 : 1056 1066.
25. McKiernan JM, Masson P, Murphy AM, Goetzl M, Olsson CA, Petrylak DP et al. (2006). Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy. J Clin Oncol 24 : 3075 3080.
26. Mollinedo F, Gajate C (2003). Microtubules, microtubule-interfering agents and apoptosis. Apoptosis 8 : 413 450.
27. Murta-Nascimento C, Schmitz-Drager BJ, Zeegers MP, Steineck G, Kogevinas M, Real FX et al. (2007). Epidemiology of urinary bladder cancer: from tumor development to patient's death. World J Urol 25 : 285 295.
28. Nabha SM, Mohammad RM, Dandashi MH, Coupaye-Gerard B, Aboukameel A, Pettit GR et al. (2002). Combretastatin-A4 prodrug induces mitotic catastrophe in chronic lymphocytic leukemia cell line independent of caspase activation and poly(ADP-ribose) polymerase cleavage. Clin Cancer Res 8 : 2735 2741.
29. Parkin DM (2008). The global burden of urinary bladder cancer. Scand J Urol Nephrol 42 (Suppl. 12 20.
30. Pettit GR, Singh SB, Hamel E, Lin CM, Alberts DS, Garcia-Kendall D (1989). Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia 45 : 209 211.
31. Pettit GR, Singh SB, Boyd MR, Hamel E, Pettit RK, Schmidt JM et al. (1995a). Antineoplastic agents. 291. Isolation and synthesis of combretastatins A-4, A-5, and A-6(1a). J Med Chem 38 : 1666 1672.
32. Pettit GR, Temple C, Jr., Narayanan VL, Varma R, Simpson MJ, Boyd MR et al. (1995b). Antineoplastic agents 322. synthesis of combretastatin A-4 prodrugs. Anticancer Drug Des 10 : 299 309.
33. Petit I, Karajannis MA, Vincent L, Young L, Butler J, Hooper AT et al. (2008). The microtubule-targeting agent CA4P regresses leukemic xenografts by disrupting interaction with vascular cells and mitochondrial-dependent cell death. Blood 111 : 1951 1961.
34. Renzi L, Gersch MS, Campbell MS, Wu L, Osmani SA, Gorbsky GJ (1997). MPM-2 antibody-reactive phosphorylations can be created in detergent-extracted cells by kinetochore-bound and soluble kinases. J Cell Sci 110 (Pt 17 2013 2025.
35. Roy R, Yang J, Moses MA (2009). Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol 27 : 5287 5297.
36. Saloustros E, Mavroudis D, Georgoulias V (2008). Paclitaxel and docetaxel in the treatment of breast cancer. Expert Opin Pharmacother 9 : 2603 2616.
37. Simoni D, Romagnoli R, Baruchello R, Rondanin R, Rizzi M, Pavani MG et al. (2006). Novel combretastatin analogues endowed with antitumor activity. J Med Chem 49 : 3143 3152.
38. Spiess PE, Czerniak B (2006). Dual-track pathway of bladder carcinogenesis: practical implications. Arch Pathol Lab Med 130 : 844 852.
39. Stevenson JP, Rosen M, Sun W, Gallagher M, Haller DG, Vaughn D et al. (2003). Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 21 : 4428 4438.
40. Tao Y, Leteur C, Calderaro J, Girdler F, Zhang P, Frascogna V et al. (2009). The aurora B kinase inhibitor AZD1152 sensitizes cancer cells to fractionated irradiation and induces mitotic catastrophe. Cell Cycle 8 : 3172 3181.
41. Thiery JP, Sleeman JP (2006). Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 7 : 131 142.
42. Tozer GM, Prise VE, Wilson J, Locke RJ, Vojnovic B, Stratford MR et al. (1999). Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res 59 : 1626 1634.
43. Vincent L, Kermani P, Young LM, Cheng J, Zhang F, Shido K et al. (2005). Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. J Clin Invest 115 : 2992 3006.
44. Vitale I, Antoccia A, Cenciarelli C, Crateri P, Meschini S, Arancia G et al. (2007). Combretastatin CA-4 and combretastatin derivative induce mitotic catastrophe dependent on spindle checkpoint and caspase-3 activation in non-small cell lung cancer cells. Apoptosis 12 : 155 166.
45. Wang LG, Liu XM, Kreis W, Budman DR (1999). The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother Pharmacol 44 : 355 361.
46. Yeh MY, Yu DS, Chen SC, Lin MS, Chang SY, Ma CP et al. (1988). Establishment and characterization of a human urinary bladder carcinoma cell line (TSGH-8301). J Surg Oncol 37 : 177 184.
47. Yoeli-Lerner M, Toker A (2006). Akt/PKB signaling in cancer: a function in cell motility and invasion. Cell Cycle 5 : 603 605.